Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Momo25on Aug 24, 2023 10:55pm
288 Views
Post# 35604798

Paul Lévesque performance

Paul Lévesque performanceWhen Paul Lvesque joined TH in March 2020, the revenue of TH was 65M, Profit margin: -24,8%, free cash flow: -5 M. More than 3 years later, the revenue is 79,7 M (june 2023), Profit margin: -45%, free cash flow: -16M
Quick maths show an increase of revenue by less than 5 millions per year, while the earnings went down almost 2 times, and the free cash flow went down 3 times.
Total debt on the balance sheet as per March 2020: 54,5 M
Total Debt as of Feb 2023: 66 M, an increase of 21%.
This is the picture of TH since Paul Lvesque joined the company. Any investor will be discouraged by such performance. 
There is no doubt in my mind, a CEO who puts the wealth of the shareholders in jeopardy has absolutely no reason to stay, even if he works for free.
<< Previous
Bullboard Posts
Next >>